Diagnostic performance of magnetic resonance imaging and targeted biopsy results in men with indwelling urinary catheters
A propensity score-matched study
DOI:
https://doi.org/10.5489/cuaj.9194Keywords:
prostate adenocarcinoma, Prostate Imaging Reporting and Data Systems version2.1 score, Catheters, prostatic biopsyAbstract
INTRODUCTION: We sought to evaluate multiparametric magnetic resonance imaging (mpMRI) findings and biopsy results in men with an indwelling catheter undergoing prostate cancer screening. mpMRI is central to the evaluation of prostate cancer. Little is known about the effect of an indwelling urinary catheter on prostate mpMRI findings and the results of subsequent biopsies.
METHODS: We retrospectively reviewed 5820 mpMRI exams performed from 2017-2023. Forty-eight patients underwent mpMRI with an indwelling urinary catheter. Using propensity score matching, patients were matched 1:1 for age, pre-biopsy prostate-specific antigen (PSA), and prostate volume. Clinical characteristics, mpMRI findings, and targeted biopsy results were compared between the groups.
RESULTS: After propensity score matching, clinical characteristics of the study groups did not differ significantly. Prostate Imaging-Reporting & Data System (PI-RADS) distribution did not show a significant difference (p=0.51); PI-RADS ≥3 lesions were identified in 20/48 (42%) patients with indwelling catheters and in 18/50 (36%) patients without catheters. Among patients with a PI-RADS score ≥3, clinically significant prostate cancer (csPCa) was identified in 5/20 patients carrying catheters and 6/18 patients without catheters (p=0.152). A higher rate of any cancer was identified in patients without a catheter (67% vs. 35%, p=0.049). PSA >9.79 ng/ml predicted the finding of csPCa in patients carrying urinary catheters with PI-RADS ≥3 lesions.
CONCLUSIONS: Our findings suggest no significant difference in mpMRI findings and csPCa rates for patients with and without indwelling urinary catheters. Patients carrying urinary catheters suspected to harbor csPCa based on an elevated PSA level should undergo further evaluation, including mpMRI and biopsies when necessary before benign prostatic hyperplasia treatment.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:
- Post the Article on any Web site
- Translate or authorize a translation of the Article
- Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
- Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.
The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.
You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.
The CUA also requires you to warrant the following:
- That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
- That all individuals who have made a substantive contribution to the article are acknowledged;
- That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
- That the Article does not libel or violate the privacy rights of any third party.
